Supernus Pharmaceuticals
SUPN
186 hedge funds and large institutions have $661M invested in Supernus Pharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 37 funds opening new positions, 75 increasing their positions, 58 reducing their positions, and 16 closing their positions.
131% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 16
29% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 58
12% more funds holding
Funds holding: 166 → 186 (+20)
1% more call options, than puts
Call options by funds: $4.51M | Put options by funds: $4.45M
9% less capital invested
Capital invested by funds: $725M → $661M (-$64.2M)
50% less funds holding in top 10
Funds holding in top 10: 8 → 4 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$25.8M |
| 2 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$21.7M |
| 3 |
KCM
Kornitzer Capital Management
Shawnee Mission,
Kansas
|
+$15.5M |
| 4 |
HP
HealthInvest Partners
Stockholm,
Sweden
|
+$14.6M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$8.66M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MRM
Michael R. Murphy
|
-$15.7M |
| 2 |
Ameriprise
Minneapolis,
Minnesota
|
-$8.28M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$8M |
| 4 |
NC
Northpointe Capital
Bloomfield Hills,
Michigan
|
-$5.65M |
| 5 |
BC
Bruce & Co
Chicago,
Illinois
|
-$5.58M |
SUPN Hedge Fund Activity: Q3 2015 in Review
186 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q3 2015, worth a combined $661M — down 8.9% from $725M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new SUPN positions and 16 closed out — a net gain of 21 holders — while 75 added to existing stakes and 58 trimmed.
The largest buyer was State Street, adding an estimated $25.8M. The largest seller was Michael R. Murphy, cutting an estimated $15.7M.
- 186 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q3 2015, up from 166 in Q2 2015.
- Funds reported $661M of Supernus Pharmaceuticals stock for Q3 2015, down 8.9% quarter-over-quarter.
- 37 funds opened new Supernus Pharmaceuticals positions in Q3 2015 and 16 closed out, a net change of +21 holders.
- The largest Supernus Pharmaceuticals buyer in Q3 2015 was State Street, an estimated $25.8M added.
- The largest Supernus Pharmaceuticals seller in Q3 2015 was Michael R. Murphy, an estimated $15.7M sold.
Based on aggregated 13F filings for Q3 2015.